Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 25, Issue -, Pages 216-218Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2018.08.006
Keywords
Multiple Sclerosis; Fingolimod; Alemtuzumab; Rebound
Categories
Funding
- Sanofi-Genzyme
- Biogen
- Roche
- Teva
- Novartis
- Merck-Serono
- Bayer
- Allmiral
Ask authors/readers for more resources
Unexpected high disease activity (UHDA) after Fingolimod withdrawal has recently become a controversial concern for physicians. Here, we report the case of a patient with severe exacerbation of MS after switching from Fingolimod to Alemtuzumab treatment. This UHDA despite profound lymphopenia raised the question of the management of sequential use of biotherapies such as Fingolimod and Alemtuzumab in MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available